Eyelash

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 9987 Experts worldwide ranked by ideXlab platform

Luisa Cikamatana - One of the best experts on this subject based on the ideXlab platform.

Frederick C Beddingfield - One of the best experts on this subject based on the ideXlab platform.

  • long term safety and efficacy of bimatoprost solution 0 03 application to the eyelid margin for the treatment of idiopathic and chemotherapy induced Eyelash hypotrichosis a randomized controlled trial
    British Journal of Dermatology, 2015
    Co-Authors: D A Glaser, Emily Weng, Parwez Hossain, W Perkins, T Griffiths, G Ahluwalia, Frederick C Beddingfield
    Abstract:

    BACKGROUND: Bimatoprost ophthalmic solution 0.03% is approved in several countries for treating Eyelash hypotrichosis. Previous trials were limited to 4 months of treatment and primarily idiopathic hypotrichosis. OBJECTIVE: Evaluate long-term safety and efficacy of bimatoprost among subjects with idiopathic or chemotherapy-induced hypotrichosis. METHODS: This multicentre, double-masked, randomised, parallel-group study included two 6-month treatment periods. Subjects with idiopathic hypotrichosis were randomised to 3 treatment groups: 1) treatment period 1 (TP1) and TP2: bimatoprost; 2) TP1: bimatoprost; TP2: vehicle; and 3) TP1: vehicle; TP2: bimatoprost. Subjects with chemotherapy-induced hypotrichosis were randomised to 2 treatment groups: 1) TP1: bimatoprost or vehicle; and 2) TP2: bimatoprost. The primary endpoint was a composite of at least a 1-grade improvement in investigator-assessed Global Eyelash Assessment (GEA), and at least a 3-point improvement in subject-reported Eyelash Satisfaction Questionnaire (ESQ) Domain 2 (self-perceived confidence, attractiveness, and professionalism) at month 4. Secondary measures included digitally assessed Eyelash characteristics (ie, Eyelash length, fullness, and darkness). RESULTS: The study randomised 368 subjects. The primary efficacy endpoint was met in both populations (responder rates: idiopathic: 40.2% bimatoprost vs 6.8% vehicle; post-chemotherapy: 37.5% bimatoprost vs 18.2% vehicle). Efficacy by month 6 was maintained (idiopathic) or enhanced (post-chemotherapy) at 12 months. Treatment effects were maintained for approximately 2 months but markedly diminished 4 to 6 months following treatment cessation in subjects with idiopathic hypotrichosis. No drug-related serious adverse events were reported. CONCLUSIONS: Daily treatment with bimatoprost ophthalmic solution 0.03% for 1 year was effective and well tolerated in subjects with idiopathic and chemotherapy-induced hypotrichosis.

  • Eyelash growth in subjects treated with bimatoprost a multicenter randomized double masked vehicle controlled parallel group study
    Journal of The American Academy of Dermatology, 2012
    Co-Authors: Stacy Smith, Emily Weng, Frederick C Beddingfield, Steven Fagien, Scott M Whitcup, Fred Ledon, Christine Somogyi
    Abstract:

    Background Bimatoprost 0.03% is associated with increased growth and prominence of Eyelashes. Objective We sought to compare the safety and efficacy of once-daily bimatoprost 0.03% versus vehicle in increasing Eyelash length, thickness, and darkness after topical administration to upper eyelid margins. Methods In this 5-month study, subjects were randomized to receive once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141). The primary end point was Eyelash prominence assessed by the investigator global Eyelash assessment scale. Secondary efficacy measures included Eyelash length, thickness, and darkness measured by digital image analysis and patient-reported outcomes. Safety data included adverse event monitoring and ophthalmic examinations. Results A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) versus vehicle (18.4%) demonstrated at least a 1-grade increase in global Eyelash assessment score at week 16 ( P P P  = .03). Limitations Short-term duration of the trial was a limitation; black subjects were not enrolled secondary to technical requirements of digital image analysis. Conclusion Bimatoprost 0.03% was found to be effective at enhancing Eyelashes in adults with a very good safety profile.

Brett A King - One of the best experts on this subject based on the ideXlab platform.

  • development of clinician reported outcome clinro and patient reported outcome pro measures for eyebrow Eyelash and nail assessment in alopecia areata
    American Journal of Clinical Dermatology, 2020
    Co-Authors: Kathleen W Wyrwich, Natalie Vj Aldhouse, H Kitchen, Sarah Knight, Jake Macey, Fabio P Nunes, Yves Dutronc, Natasha Atanaskova Mesinkovska, Brett A King
    Abstract:

    Eyebrow and Eyelash hair loss and nail damage—in addition to scalp hair loss—are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment in AA clinical trials. Our objective was to develop clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures and accompanying photoguides to aid in the assessment of AA-related eyebrow, Eyelash and nail signs/symptoms. Iterative rounds of qualitative, semi-structured interviews were conducted with US expert dermatologists and North American patients with AA. Patients with eyebrow, Eyelash and nail involvement were purposefully sampled. Interview transcripts were qualitatively analyzed. Dermatologists (n = 10) described eyebrow and Eyelash loss as concerning for affected patients and, along with nail appearance, as deserving assessment. Dermatologist data informed the development of single item, 4-point Likert-type ClinRO and PRO measures of current eyebrow loss, Eyelash loss and nail appearance and a PRO measure of eye irritation. Patients (n = 45, age 15–72 years) confirmed the importance and relevance of these signs/symptoms. Interim revision resulted in measures that were understood by and relevant to patients. Dermatologists (n = 5) and patients (n = 10, age 21–54 years) participated in the development of the eyebrow, Eyelash and nail photoguides and confirmed that they included photos that appropriately represented different severity levels and were helpful to derive and standardize ratings across raters. The ClinRO and PRO measures for eyebrow, Eyelash and nail appearance, with their accompanying photoguides and the PRO Measure for Eye Irritation provide clear and meaningful assessments of outcomes important to patients with AA.

Elke Lütjen-drecoll - One of the best experts on this subject based on the ideXlab platform.

  • Characterization of an in vivo model for the study of Eyelash biology and trichomegaly: mouse Eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost.
    The British journal of dermatology, 2010
    Co-Authors: Miyuki Tauchi, T. A. Fuchs, A.j. Kellenberger, D.f. Woodward, Ralf Paus, Elke Lütjen-drecoll
    Abstract:

    BACKGROUND: Hypertrichosis or alopecia of the Eyelashes is associated with various diseases or may be drug induced. Although neither increase nor loss of Eyelashes is life threatening, Eyelash disorders can be psychologically disturbing. However, as control of Eyelash growth and the underlying mechanisms of Eyelash hypo- or hypertrichosis are largely obscure, available therapy is limited. OBJECTIVES: To improve this situation, we sought to establish a pragmatic, well-defined mouse model for the study and pharmacological investigation of Eyelash follicle biology. METHODS: ? We took a morphometric approach to establish an Eyelash model using female C57BL/6J mice by comparing with pelage hairs and highlighting the differences. We next applied a hypertrichosis-triggering agent and investigated its effect using the model. RESULTS: In Eyelashes, a synchronized growth cycle was observed after morphogenesis but was completed earlier than pelage hairs. Exogen was strictly regulated and occurred in every cycle in the Eyelash. Otherwise, general morphological features of mouse Eyelashes (shafts, follicles, morphogenesis and growth cycle) were comparable with those of pelage hairs. The Eyelash growth-stimulatory agent in humans, bimatoprost, significantly extended the duration of anagen, resulting in more and longer Eyelashes, but there was no evidence of follicle neogenesis. CONCLUSIONS: This study shows that mouse Eyelashes offer an excellent in vivo model for the quantitative and qualitative analysis of Eyelash morphology, development, growth cycle, exogen and pharmacological modulation. This model will help to elucidate the unknown molecular controls of Eyelash growth, and to develop novel drugs to treat Eyelash disorders.

Colin Macleod - One of the best experts on this subject based on the ideXlab platform.

Related terms

Eyelash - 15 days free trial to Access Experts & Abstracts